Valneva has been granted a patent for their CpG-adjuvanted SARS-CoV-2 vaccine. The vaccine includes an inactivated SARS-CoV-2 whole virus particle, a CpG-containing oligodeoxynucleotide, and an alum adjuvant. It is designed to induce neutralizing antibodies without causing antibody-dependent enhancement of SARS-CoV-2-associated disease. GlobalData’s report on Valneva gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Valneva, anti-viral antigen-based compositions was a key innovation area identified from patents. Valneva's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Cpg-adjuvanted sars-cov-2 vaccine composition inducing neutralizing antibodies
A recently granted patent (Publication Number: US11684669B2) describes a composition for immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the COVID-19 pandemic. The composition includes an inactivated SARS-CoV-2 whole virus particle, a CpG-containing oligodeoxynucleotide (CpG-ODN), and an alum adjuvant. The composition is designed to induce the production of neutralizing antibodies against SARS-CoV-2 when administered intramuscularly. Importantly, the composition does not cause antibody-dependent enhancement of SARS-CoV-2-associated disease.
The inactivated SARS-CoV-2 whole virus particle in the composition has an S protein with at least 96% amino acid sequence identity to a specific sequence (SEQ ID NO: 3). The alum adjuvant used is aluminum hydroxide. The ratio of alum to CpG-ODN in the composition ranges from about 1:3 to about 3:1, with a preferred ratio of about 1:2. The alum content in the composition is between about 0.8 to about 1.2 mg/mL, with a preferred content of about 1 mg/mL. The CpG-ODN content in the composition is between about 1.5 to about 2.5 mg/mL, with a preferred content of about 2 mg/mL.
The amount of inactivated SARS-CoV-2 whole virus particles per dose in the composition is between about 0.25 and about 2.5 milli-absorption units×minutes (mAU) as assessed by size exclusion chromatography-high performance liquid chromatography (SEC-HPLC). Alternatively, the amount can be determined as 35 Antigen Units using a SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) assay.
The patent also describes a kit that includes the SARS-CoV-2 immunogenic composition along with a second immunogenic composition. The second composition can be another SARS-CoV-2 virus immunogenic composition or a composition for immunization against other viruses such as Japanese encephalitis virus, Zika virus, Dengue virus, influenza virus, or Chikungunya virus.
The patent further includes a method for producing the SARS-CoV-2 immunogenic composition. The method involves producing SARS-CoV-2 whole virus particles with the desired S protein sequence, inactivating the particles, and incorporating them into the immunogenic composition along with the CpG-ODN and alum adjuvant.
Overall, this patent provides a detailed description of a composition and method for immunization against SARS-CoV-2, offering potential insights for the development of effective COVID-19 vaccines.
To know more about GlobalData’s detailed insights on Valneva, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
